This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982; 307: 913–6.VeronesiUAdamusJAubertCBajettaEBerettaGBonadonnaGA randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanomaN Engl J Med1982307913610.1056/NEJM198210073071503Search in Google Scholar
Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, et al. Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma”. J Dtsch Dermatol Ges 2013; 11 (Suppl 6): 1–116, 1-126.PflugfelderAKochsCBlumACapellaroMCzeschikCDettenbornTMalignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma”J Dtsch Dermatol Ges201311(Suppl 6)11161-12610.1111/ddg.12113_supplSearch in Google Scholar
Hauschild A. Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations? Curr Oncol 2009; 16: 3–6.HauschildAAdjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?Curr Oncol2009163610.3747/co.v16i3.447Search in Google Scholar
Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996; 14: 2666–73.ColeBFGelberRDKirkwoodJMGoldhirschABarylakEBordenEQuality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group studyJ Clin Oncol19961426667310.1200/JCO.1996.14.10.2666Search in Google Scholar
Grob JJ, Dreno B, de la Salmonière P, Delaunay M, Cupissol D, Guillot B, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998; 351: 1905–10.GrobJJDrenoBde la SalmonièrePDelaunayMCupissolDGuillotBRandomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on MelanomaLancet199835119051010.1016/S0140-6736(97)12445-XSearch in Google Scholar
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471–4.EdgeSBComptonCCThe American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNMAnn Surg Oncol2010171471410.1245/s10434-010-0985-420180029Search in Google Scholar
Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102: 493–501.MocellinSPasqualiSRossiCRNittiDInterferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysisJ Natl Cancer Inst201010249350110.1093/jnci/djq00920179267Search in Google Scholar
Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev 2013; 6: CD08955.MocellinSLensMBPasqualiSPilatiPChiarion SileniVInterferon alpha for the adjuvant treatment of cutaneous melanomaCochrane Database Syst Rev20136>CD00895510.1002/14651858.CD008955Search in Google Scholar
Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013; 10: 588–98.KaufmanHLKirkwoodJMHodiFSAgarwalaSAmatrudaTBinesSDThe Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanomaNat Rev Clin Oncol2013105889810.1038/nrclinonc.2013.15323982524Search in Google Scholar
Karimkhani C, Gonzalez R, Dellavalle RP. A review of novel therapies for melanoma. Am J Clin Dermatol 2014; 15: 323–37.KarimkhaniCGonzalezRDellavalleRPA review of novel therapies for melanomaAm J Clin Dermatol2014153233710.1007/s40257-014-0083-724928310Search in Google Scholar
Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours. EJSO 2008; 34: 232–40.SersaGMiklavcicDCemazarMRudolfZPuciharGSnojMElectrochemotherapy in treatment of tumoursEJSO2008342324010.1016/j.ejso.2007.05.01617614247Search in Google Scholar
Testori A, Rossi CR, Tosti G. Utility of electrochemotherapy in melanoma treatment. Curr Opin Oncol 2012; 24: 155–61.TestoriARossiCRTostiGUtility of electrochemotherapy in melanoma treatmentCurr Opin Oncol2012241556110.1097/CCO.0b013e32834fcaa822249204Search in Google Scholar
Cadossi R, Ronchetti M, Cadossi M. Locally enhanced chemotherapy by electroporation: clinical experiences and perspective of use of electrochemotherapy. Future Oncol 2014; 10: 877–90.CadossiRRonchettiMCadossiMLocally enhanced chemotherapy by electroporation: clinical experiences and perspective of use of electrochemotherapyFuture Oncol2014108779010.2217/fon.13.23524799067Search in Google Scholar
Testori A, Faries MB, Thompson JF, Pennacchioli E, Deroose JP, van Geel AN, et al. Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol 2011; 104: 391–6.TestoriAFariesMBThompsonJFPennacchioliEDerooseJPvan GeelANLocal and intralesional therapy of in-transit melanoma metastasesJ Surg Oncol2011104391610.1002/jso.2202921858834Search in Google Scholar
Edhemovic I, Brecelj E, Gasljevic G, Marolt Music M, Gorjup V, Mali B, et al. Intraoperative electrochemotherapy of colorectal liver metastases. J Surg Oncol 2014; 110: 320–7.EdhemovicIBreceljEGasljevicGMarolt MusicMGorjupVMaliBIntraoperative electrochemotherapy of colorectal liver metastasesJ Surg Oncol2014110320710.1002/jso.2362524782355Search in Google Scholar
Marty M, Sersa G, Garbay J, Gehl J, Collins C, Snoj M, et al. Electrochemotherapy–An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 2006; 4: 3–13.MartyMSersaGGarbayJGehlJCollinsCSnojMElectrochemotherapy– Aneasy highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) studyEur J Cancer Suppl2006431310.1016/j.ejcsup.2006.08.002Search in Google Scholar
Simeone E, Benedetto L, Gentilcore G, Capone M, Caraco C, Di Monta G, et al. Combination therapy with ipilimumab and electrochemotherapy; preliminary efficacy results and correlation with imunological parameters. J Transl Med 2014; 12 (Suppl 1): 05.SimeoneEBenedettoLGentilcoreGCaponeMCaracoCDi MontaGCombination therapy with ipilimumab and electrochemotherapy; preliminary efficacy results and correlation with imunological parametersJ Transl Med201412Suppl 10510.1186/1479-5876-12-S1-O5Search in Google Scholar
Valpone S, Campana L, Pigozzo J, Chiarion-Sileni V. Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib. Radiol Oncol 2015; 49: 71–4.ValponeSCampanaLPigozzoJChiarion-SileniVConsolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenibRadiol Oncol20154971410.2478/raon-2014-0035436260925810704Search in Google Scholar
Cemazar M, Jarm T, Sersa G. Cancer electrogene therapy with interleukin-12. Curr Gene Ther 2010; 10: 300–11.CemazarMJarmTSersaGCancer electrogene therapy with interleukin-12Curr Gene Ther2010103001110.2174/15665231079182342520560875Search in Google Scholar
Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896–903.DaudAIDeContiRCAndrewsSUrbasPRikerAISondakVKPhase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanomaJ Clin Oncol200826589690310.1200/JCO.2007.15.6794264511119029422Search in Google Scholar
Spanggaard I, Snoj M, Cavalcanti A, Bouquet C, Sersa G, Robert C, et al. Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study. Hum Gene Ther Clin Dev 2013; 24: 99–107.SpanggaardISnojMCavalcantiABouquetCSersaGRobertCGene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man studyHum Gene Ther Clin Dev2013249910710.1089/humc.2012.240Search in Google Scholar
Heller LC, Heller R. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 2010; 10: 312–7.HellerLCHellerRElectroporation gene therapy preclinical and clinical trials for melanomaCurr Gene Ther201010312710.2174/156652310791823489Search in Google Scholar
Cemazar M, Todorovic V, Scancar J, Lampreht U, Stimac M, Kamensek U, et al. Adjuvant TNF-α therapy to electrochemotherapy with intravenous cisplatin in murine sarcoma exerts synergistic antitumor effectiveness. Radiol Oncol 2015; 49: 32–40.CemazarMTodorovicVScancarJLamprehtUStimacMKamensekUAdjuvant TNF-α therapy to electrochemotherapy with intravenous cisplatin in murine sarcoma exerts synergistic antitumor effectivenessRadiol Oncol201549324010.1515/raon-2015-0005Search in Google Scholar
Gerlini G, Di Gennaro P, Borgognoni L. Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation. Oncoimmunology 2012; 1: 1655–7.GerliniGDi GennaroPBorgognoniLEnhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activationOncoimmunology201211655710.4161/onci.21991Search in Google Scholar
Sersa G, Cemazar M, Menart V, Gaberc-Porekar V, Miklavcic D. Anti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNF-alpha on SA-1 tumors in mice. Cancer Lett 1997; 116: 85–92.SersaGCemazarMMenartVGaberc-PorekarVMiklavcicDAnti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNF-alpha on SA-1 tumors in miceCancer Lett1997116859210.1016/S0304-3835(97)00170-5Search in Google Scholar
Heller L, Pottinger C, Jaroszeski MJ, Gilbert R, Heller R. In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res 2000; 10: 577–83.HellerLPottingerCJaroszeskiMJGilbertRHellerRIn vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunityMelanoma Res2000105778310.1097/00008390-200012000-0001011198480Search in Google Scholar
Mir LM, Roth C, Orlowski S, Belehradek J, Fradelizi D, Paoletti C, et al. Potentiation of the antitumoral effect of electrochemotherapy by immunotherapy with allogeneic cells producing interleukin 2. C R Acad Sci III 1992; 314: 539–44.MirLMRothCOrlowskiSBelehradekJFradeliziDPaolettiCPotentiation of the antitumoral effect of electrochemotherapy by immunotherapy with allogeneic cells producing interleukin 2C R Acad Sci III199231453944Search in Google Scholar
Mir LM, Orlowski S, Poddevin B, Belehradek J. Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host’s defenses. Eur Cytokine Netw 1992; 3: 331–4.MirLMOrlowskiSPoddevinBBelehradekJElectrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host’s defensesEur Cytokine Netw199233314Search in Google Scholar
Roux S, Bernat C, Al-Sakere B, Ghiringhelli F, Opolon P, Carpentier AF, et al. Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother 2008; 57: 1291–300.RouxSBernatCAl-SakereBGhiringhelliFOpolonPCarpentierAFTumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responsesCancer Immunol Immunother200857129130010.1007/s00262-008-0462-018259749Search in Google Scholar
Sedlar A, Dolinsek T, Markelc B, Prosen L, Kranjc S, Bosnjak M, et al. Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity. Radiol Oncol 2012; 46: 302–11.SedlarADolinsekTMarkelcBProsenLKranjcSBosnjakMPotentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicityRadiol Oncol2012463021110.2478/v10019-012-0044-9357289323412658Search in Google Scholar
Moreno Nogueira JA, 1 Valero Arbizu M, Pérez Temprano R. Adjuvant treatment of melanoma. ISRN Dermatol. 2013; 2013: 545631.Moreno NogueiraJAValero ArbizuMPérez TempranoRAdjuvant treatment of melanomaISRN Dermatol.2013201354563110.5772/19242Search in Google Scholar
Groselj A, Kos B, Cemazar M, Urbancic J, Kragelj G, Bosnjak M, Veberic B, Strojan P, Miklavcic D, Sersa G. Coupling treatment planning with navigation system: a new technological approach in treatment of head and neck tumors by electrochemotherapy. Biomed Eng Online. 2015; 14 Suppl 3: S2.GroseljAKosBCemazarMUrbancicJKrageljGBosnjakMVebericBStrojanPMiklavcicDSersaGCoupling treatment planning with navigation system: a new technological approach in treatment of head and neck tumors by electrochemotherapyBiomed Eng Online.201514Suppl 3S210.1186/1475-925X-14-S3-S2456557526355773Search in Google Scholar
Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. EJSO 2013; 39: 4–16.MaliBJarmTSnojMSersaGMiklavcicDAntitumor effectiveness of electrochemotherapy: a systematic review and meta-analysisEJSO20133941610.1016/j.ejso.2012.08.016Search in Google Scholar
Calvet CY, Famin D, André FM, Mir LM. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology 2014; 3: e28131.CalvetCYFaminDAndréFMMirLMElectrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cellsOncoimmunology20143e2813110.4161/onci.28131Search in Google Scholar
Sersa G, Miklavcic D, Cemazar M, Belehradek J, Jarm T, LM. Mir. Electrochemotherapy with CDDP on LPB sarcoma: comparison of the anti-tumor effectiveness in immunocompetent and immunodeficient mice. Bioelectrochem Bioenerg 1997; 43: 279–83.SersaGMiklavcicDCemazarMBelehradekJJarmT LMMirElectrochemotherapy with CDDP on LPB sarcoma: comparison of the anti-tumor effectiveness in immunocompetent and immunodeficient miceBioelectrochem Bioenerg1997432798310.1016/S0302-4598(96)05194-XSearch in Google Scholar
Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996; 272: 1947–50.ToughDFBorrowPSprentJInduction of bystander T cell proliferation by viruses and type I interferon in vivoScience199627219475010.1126/science.272.5270.19478658169Search in Google Scholar
Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, et al. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 1998; 64: 358–67.PaquetteRLHsuNCKiertscherSMParkANTranLRothMDInterferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cellsJ Leukoc Biol1998643586710.1002/jlb.64.3.3589738663Search in Google Scholar
Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7: 95–106.MeleroIHervas-StubbsSGlennieMPardollDMChenLImmunostimulatory monoclonal antibodies for cancer therapyNat Rev Cancer200779510610.1038/nrc205117251916Search in Google Scholar
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23.HodiFSO’DaySJMcDermottDFWeberRWSosmanJAHaanenJBImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med20103637112310.1056/NEJMoa1003466354929720525992Search in Google Scholar
O’Brien MA, Power DG, Clover AJ, Bird B, Soden DM, Forde PF. Local tumour ablative therapies: opportunities for maximising immune engagement and activation. Biochim Biophys Acta 2014; 1846: 510–23.O’BrienMAPowerDGCloverAJBirdBSodenDMFordePFLocal tumour ablative therapies: opportunities for maximising immune engagement and activationBiochim Biophys Acta201418465102310.1016/j.bbcan.2014.09.00525286319Search in Google Scholar
Sersa G, Kotnik V, Cemazar M, Miklavcic D, Kotnik A. Electrochemotherapy with bleomycin in SA-1 tumor-bearing mice--natural resistance and immune responsiveness. Anticancer Drugs 1996; 7: 785–91.SersaGKotnikVCemazarMMiklavcicDKotnikAElectrochemotherapy with bleomycin in SA-1 tumor-bearing mice--natural resistance and immune responsivenessAnticancer Drugs199677859110.1097/00001813-199609000-000118949991Search in Google Scholar
Sersa G, Teissie J, Signori E, Kamensek U, Marshall G, Cemazar M, et al. Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother 2015; 64: 1315–27.SersaGTeissieJSignoriEKamensekUMarshallGCemazarMElectrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransferCancer Immunol Immunother20156413152710.1007/s00262-015-1724-2455473526067277Search in Google Scholar
